Detalhe da pesquisa
1.
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.
Lancet HIV
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38734016
2.
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.
Antivir Ther
; 24(6): 425-435, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31355775
3.
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Lancet HIV
; 4(12): e536-e546, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28729158
4.
Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.
Antivir Ther
; 20(3): 343-8, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25321146
5.
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Lancet Infect Dis
; 15(10): 1145-1155, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26201299
6.
Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients.
J Int AIDS Soc
; 17(4 Suppl 3): 19532, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25394041